Neurocrine Biosciences | NBIX - Net Income


Neurocrine Biosciences reported $209.5M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Exelixis USD 193.58M 8.73M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
Halozyme Therapeutics USD 175.22M 10.06M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -36.54M 89.23M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Repligen USD 14.91M 44K Sep/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Teva Pharmaceutical Industries USD 480M 47M Dec/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025